Equities

Top KingWin Ltd

TCJH:NAQ

Top KingWin Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.3356
  • Today's Change0.011 / 3.36%
  • Shares traded66.98k
  • 1 Year change-68.49%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 20:57 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Top KingWin Ltd had net income fall 230.23% from a loss of 771.48k to a larger loss of 2.55m despite a 74.65% increase in revenues from 3.12m to 5.45m. An increase in the selling, general and administrative costs as a percentage of sales from 98.80% to 111.28% was a component in the falling net income despite rising revenues.
Gross margin65.84%
Net profit margin-46.72%
Operating margin-45.43%
Return on assets-33.25%
Return on equity-55.22%
Return on investment-52.20%
More ▼

Cash flow in USDView more

In 2023, Top KingWin Ltd increased its cash reserves by 75.16%, or 1.99m. Cash Flow from Financing totalled 7.77m or 142.54% of revenues. In addition the company used 1.65m for operations while cash used for investing totalled 4.06m.
Cash flow per share--
Price/Cash flow per share--
Book value per share0.5020
Tangible book value per share0.2973
More ▼

Balance sheet in USDView more

Top KingWin Ltd has little financial risk as the capital structure does not rely on leverage.
Current ratio2.48
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items dropped -184.12%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago
--
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.